812
Views
44
CrossRef citations to date
0
Altmetric
Functional disorder

Mast cell number, substance P and vasoactive intestinal peptide in irritable bowel syndrome with diarrhea

, , , , , , , , & show all
Pages 43-51 | Received 27 Jul 2013, Accepted 16 Oct 2013, Published online: 21 Nov 2013

References

  • Choung RS, Locke GR 3rd. Epidemiology of IBS. Gastroenterol Clin North Am 2011;40:1–10.
  • Camilleri M, Andresen V. Current and novel therapeutic options for irritable bowel syndrome management. Dig Liver Dis 2009;41:854–62.
  • Ford AC, Talley NJ. Mucosal inflammation as a potential etiological factor in irritable bowel syndrome: a systematic review. J Gastroenterol 2011;46:421–31.
  • Ohman L, Simren M. Pathogenesis of IBS: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol 2010;7:163–73.
  • Santos J, Guilarte M, Alonso C, Malagelada JR. Pathogenesis of irritable bowel syndrome: the mast cell connection. Scand J gastroenterol 2005;40:129–40.
  • Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am J Surg Pathol 2007;31:1669–76.
  • Kennelly R, Conneely JB, Bouchier-Hayes D, Winter DC. Mast cells in tissue healing: from skin to the gastrointestinal tract. Curr Pharm Des 2011;17:3772–5.
  • Bischoff SC, Wedemeyer J, Herrmann A, Meier PN, Trautwein C, Cetin Y, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology 1996;28:1–13.
  • De Winter BY, van den Wijngaard RM, de Jonge WJ. Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta 2012;1822:66–73.
  • van Diest SA, Stanisor OI, Boeckxstaens GE, de Jonge WJ, van den Wijngaard RM. Relevance of mast cell-nerve interactions in intestinal nociception. Biochim Biophys Acta 2012;1822:74–84.
  • Lovell RM, Ford AC. Effect of gender on prevalence of irritable bowel syndrome in the community: systematic review and meta-analysis. Am J Gastroenterol 2012;107:991–1000.
  • Cremon C, Gargano L, Morselli-Labate AM, Santini D, Cogliandro RF, De Giorgio R, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392–400.
  • Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262–72.
  • Drossman DA. Rome III: the new criteria. Chin J Dig Dis 2006;7:181–5.
  • Weller CL, Collington SJ, Williams T, Lamb JR. Mast cells in health and disease. Clin Sci 2011;120:473–84.
  • Bischoff SC. Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 2009;31:185–205.
  • Ramsay DB, Stephen S, Borum M, Voltaggio L, Doman DB. Mast cells in gastrointestinal disease. Gastroenterol Hepatol 2010;6:772–7.
  • Kirsch R, Riddell RH. Histopathological alterations in irritable bowel syndrome. Mod Pathol 2006;19:1638–45.
  • Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, et al. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012;36:1009–31.
  • Jensen RT. Gastrointestinal abnormalities and involvement in systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:579–623.
  • Lee JK, Whittaker SJ, Enns RA, Zetler P. Gastrointestinal manifestations of systemic mastocytosis. World J Gastroenterol 2008;14:7005–8.
  • Cooke HJ. Role of the "little brain" in the gut in water and electrolyte homeostasis. FASEB J 1989;3:127–38.
  • Rijnierse A, Nijkamp FP, Kraneveld AD. Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome. Pharmacol Ther 2007;116:207–35.
  • Koon HW, Pothoulakis C. Immunomodulatory properties of substance P: the gastrointestinal system as a model. Ann N Y Acad Sci 2006;1088:23–40.
  • O'Connor TM, O'Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F. The role of substance P in inflammatory disease. J Cell Physiol 2004;201:167–80.
  • Snoek SA, Borensztajn KS, van den Wijngaard RM, de Jonge WJ. Neuropeptide receptors in intestinal disease: physiology and therapeutic potential. Curr Pharm Des 2010;16:1091–105.
  • Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, et al. Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004;49:1236–43.
  • Krejs GJ, Fordtran JS, Fahrenkrug J, Schaffalitzky de Muckadell OB, Fischer JE, Humphrey CS, et al. Effect of VIP infusion in water and ion transport in the human jejunum. Gastroenterology 1980;78:722–7.
  • Love JA, Szurszewski JH. The electrophysiological effects of vasoactive intestinal polypeptide in the guinea-pig inferior mesenteric ganglion. J physiol 1987;394:67–84.
  • Zhang H, Yan Y, Shi R, Lin Z, Wang M, Lin L. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008;78:72–6.
  • Simren M, Stotzer PO, Sjovall H, Abrahamsson H, Bjornsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2003;15:55–62.
  • Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.
  • Dong WZ, Zou DW, Li ZS, Zou XP, Zhu AY, Xu GM, et al. Study of visceral hypersensitivity in irritable bowel syndrome. Chin J Dig Dis 2004;5:103–9.
  • Akbar A, Yiangou Y, Facer P, Walters JRF, Anand P, Ghosh S. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain. Gut 2008;57:923–9.
  • Wu H-G, Jiang B, Zhou E-H, Shi Z, Shi D-R, Cui Y-H, et al. Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion. Dig Dis Sci 2008;53:1644–51.
  • Heitkemper MM, Jarrett ME. Update on irritable bowel syndrome and gender differences. Nutr Clin Pract 2008;23:275–83.
  • Voss U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol 2012:473–97.
  • Vliagoftis H, Dimitriadou V, Boucher W, Rozniecki JJ, Correia I, Raam S, et al. Estradiol augments while tamoxifen inhibits rat mast cell secretion. Int Arch Allergy Immunol 1992;98:398–409.
  • Park CH, Joo YE, Choi SK, Rew JS, Kim SJ, Lee MC. Activated mast cells infiltrate in close proximity to enteric nerves in diarrhea-predominant irritable bowel syndrome. J Korean Med Sci 2003;18:204–10.
  • Park JH, Rhee PL, Kim HS, Lee JH, Kim YH, Kim JJ, et al. Mucosal mast cell counts correlate with visceral hypersensitivity in patients with diarrhea predominant irritable bowel syndrome. J Gastroenterol Hepatol 2006;21:71–8.
  • Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK, Cho SW. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol 2008;23:1689–94.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.